immunotherapy – Page 5

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy

By MedXY 10/17/2025

This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.

Nephrology news Oncology

Advancing First-Line Treatment for Advanced Renal Cell Carcinoma: Efficacy of Benmelstobart Plus Anlotinib versus Sunitinib

By MedXY 10/16/2025

This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.

Clinical Updates news Oncology Urology

Neoadjuvant TAR-200 Plus Cetrelimab versus Cetrelimab Monotherapy in Muscle-Invasive Bladder Cancer Ineligible for Cisplatin: Interim Phase 2 Trial Analysis

By MedXY 10/15/2025

Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients ineligible for cisplatin, with manageable safety.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Specialties

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

By MedXY 10/14/2025

A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therapeutic escalation strategies.

Clinical Updates Oncology Specialties

Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics

By MedXY 09/30/2025

Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these microbes to improve treatment efficacy and overcome resistance.

Clinical Updates Oncology Specialties

Advancing Immunotherapy in Head and Neck Cancer: A Curcumin-Based Polymer Prodrug Nanoplatform Targeting Cancer Stemness and Tumor Microenvironment

By MedXY 09/29/2025

A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.

AI news Oncology Radiology Specialties

Advancing Precision Medicine in Hepatocellular Carcinoma: Machine Learning Radiomic Models Surpass Clinical Biomarkers in Predicting Immunotherapy Outcomes

By MedXY 09/27/2025

Integrated radiomic-clinical machine learning models outperform traditional clinical biomarkers in predicting survival and treatment response in unresectable hepatocellular carcinoma patients undergoing atezolizumab plus bevacizumab therapy.

news Oncology Specialties

Pembrolizumab Plus Platinum-Based Chemotherapy Shows Promise in Advanced Penile Cancer: Results from the HERCULES Trial

By MedXY 09/25/2025

The HERCULES trial demonstrates that pembrolizumab combined with platinum-based chemotherapy yields a 39.4% response rate and manageable safety in advanced penile squamous cell carcinoma, offering new hope for this underserved cancer population.

Clinical Updates news Oncology Specialties

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

By MedXY 09/24/2025

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.

$Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial$

Clinical Updates news Oncology Specialties

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

By MedXY 09/21/2025

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with limited treatment options.

news Oncology Specialties

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

By MedXY 09/21/2025

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the study before phase III.

Clinical Updates General Surgery news Oncology Specialties

Innovative Combination of Cryoablation and Intratumoral Immunotherapy Extends Survival in Advanced Metastatic Cancer

By MedXY 09/21/2025

A phase II trial demonstrates that multiplex intratumoral immunotherapy combining cryoablation with low-dose immune checkpoint inhibitors significantly prolongs median overall survival to 20.9 months in treatment-refractory metastatic solid tumors.

Allergy & Immunology Medical News news Oncology Specialties

Why Do Chimpanzees Rarely Get Cancer? Unveiling a Key Evolutionary Difference That Could Revolutionize Immunotherapy

By MedXY 09/14/2025

New research reveals that a protein called plasmin weakens human immune response against cancer compared to chimpanzees, offering promising strategies to enhance cancer immunotherapy.

Clinical Updates news Oncology Specialties

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates Oncology Specialties

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.

Clinical Updates Infectious Diseases news

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.

Clinical Updates news Oncology

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

By MedXY 09/04/2025

A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Promising Immunotherapy Combination Shows Durable Responses in Advanced Gynecological Clear Cell Cancers

By MedXY 08/23/2025

A nonrandomized trial reveals that combined nivolumab and ipilimumab treatment achieves a 54% response rate with durable effects in advanced ovarian and endometrial clear cell cancers, addressing critical unmet therapeutic needs.

Oncology Specialties

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response

By MedXY 08/23/2025

New research reveals that high-dose vitamin C selectively kills LKB1-mutant NSCLC cells by inducing pyroptosis, reversing immunotherapy resistance and improving T cell infiltration through GLUT1-mediated uptake and ROS-mediated cell death.